Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 19/20 | 0.74 |
| ▸ | KDM2B | Q8NHM5 | 9/20 | 0.74 |
| ▸ | JMJD6 | Q6NYC1 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | KDM6B | O15054 | 1/20 | 0.56 |
| ▸ | KDM5C | P41229 | 1/20 | 0.56 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.56 |
| ▸ | KDM3A | Q9Y4C1 | 1/20 | 0.56 |
| ▸ | KDM5A | P29375 | 7/20 | 0.50 |
| ▸ | KDM5B | Q9UGL1 | 7/20 | 0.50 |
| ▸ | KDM4A | O75164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16034412 | 0.85 | KDM4C (1.00) | KDM4CKDM2BKDM5AKDM5BKDM4A | |
| SCHEMBL29894587 | 0.78 | KDM4E (0.86) | KDM4CJMJD6KDM4EKDM6BKDM5C | |
| SCHEMBL70279 | 0.78 | KDM4E (0.86) | KDM4CJMJD6KDM4EKDM6BKDM5C | |
| SCHEMBL6514670 | 0.76 | KDM4E (0.83) | KDM4CJMJD6KDM4EKDM6BKDM5C | |
| Hydrochloric Acid SCHEMBL6504834 | 0.76 | KDM4E (0.83) | KDM4CJMJD6KDM4EKDM6BKDM5C | |
| SCHEMBL19737998 | 0.75 | NPSR1 (0.43) | KDM4CKDM2BJMJD6KDM4E | |
| SCHEMBL16034635 | 0.75 | KDM4C (0.79) | KDM4CKDM2BKDM5AKDM5BKDM4A | |
| SCHEMBL14944871 | 0.74 | KDM4E (0.73) | KDM4CJMJD6KDM4EKDM6BKDM5C | |
| SCHEMBL16107415 | 0.74 | KDM4E (0.60) | KDM4CKDM2BJMJD6KDM4EKDM6B | |
| SCHEMBL20761894 | 0.74 | JMJD6 (0.64) | KDM4CJMJD6KDM4EKDM6BKDM5C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2969007-B1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RES INC (US) | 2019-05-08 | — | — | EP | disclosed |
| US-10273222-B2 | Histone demethylase inhibitors | CELGENE QUANTSCEL RESEARCH, INC. (US) | 2019-04-30 | — | — | US | disclosed |
| US-9963441-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-05-08 | — | — | US | disclosed |
| US-20170334879-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RES INC (US) | 2017-11-23 | — | — | US | disclosed |
| US-9701657-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2017-07-11 | — | — | US | disclosed |
| US-20170066739-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE PHARMACEUTICALS INC (US) | 2017-03-09 | — | — | US | disclosed |
| US-9527829-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2016-12-27 | — | — | US | disclosed |
| US-20160122314-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC | 2016-05-05 | — | — | US | disclosed |
| US-20160113914-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. | 2016-04-28 | — | — | US | disclosed |
| EP-2969007-A1 | HISTONE DEMETHYLASE INHIBITORS | Quanticel Pharmaceuticals Inc (US) | 2016-01-20 | — | — | EP | disclosed |
| US-9133166-B2 | Histone demethylase inhibitors | Quanticel Pharmaceuticals, Inc. (US) | 2015-09-15 | — | — | US | disclosed |
| WO-2014151945-A1 | HISTONE DEMETHYLASE INHIBITORS | Quanticel Pharmaceuticals, Inc. (US) | 2014-09-25 | — | — | WO | disclosed |
| US-20140275084-A1 | HISTONE DEMETHYLASE INHIBITORS | Quanticel Pharmaceuticals, Inc. (US) | 2014-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10273222-B2 | Histone demethylase inhibitors | KDM1B, KDM1A, KDM3B | KDM4C 13/4885KDM2B 19/4885JMJD6 15/4885 |
| US-20170066739-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM1A, KDM3B | KDM4C 13/4885KDM2B 19/4885JMJD6 15/4885 |
| US-20170334879-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM1A, KDM3B | KDM4C 13/4885KDM2B 19/4885JMJD6 15/4885 |
| US-20140275084-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM1A, KDM3B | KDM4C 13/4885KDM2B 19/4885JMJD6 15/4885 |
| US-20160122314-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM1A, KDM3B | KDM4C 13/4885KDM2B 19/4885JMJD6 15/4885 |
| US-20160113914-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM1A, KDM3B | KDM4C 13/4885KDM2B 19/4885JMJD6 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.